Peptide Therapy
44 articles on Peptide Therapy, written by Shotlee and medically reviewed for clinical accuracy.
Retatrutide Trials: Why Extreme Weight Loss Isn't Always Safe
Clinical trials for the triple-agonist Retatrutide show promising weight loss, but 11% of high-dose participants dropped out due to side effects.
7 min read
Beyond the Hype: Understanding the Rise of Peptide Therapy
Peptide therapy is gaining traction, with compounds like semaglutide revolutionizing weight management. But what exactly are peptides, and what are the realities behind the trending 'peptide summer'? This article delves into the science, the risks, and the future of this evolving field.
7 min read
Peptide Therapy Science: Weighing Benefits and Risks
Peptides offer targeted health benefits, from weight loss to injury healing, but safety varies significantly. Explore the science, risks, and medical guidance required.
7 min read
FDA Warning: How to Spot Fake Tirzepatide and Stay Safe on Weight Loss
The FDA has issued a critical warning regarding counterfeit tirzepatide products. Discover the risks of fake GLP-1 medications and how to verify legitimate sources for your weight loss journey.
6 min read
Peptide Use Among Young Men: The Pursuit of Perfection and Potential Risks
The quest for physical perfection is driving a new trend among teen boys and young men: the use of unapproved peptides. This article delves into the motivations, the substances involved, and the significant health concerns surrounding this practice.
8 min read
Beyond Ozempic: Kris Jenner's Peptide Therapy Journey
Kris Jenner reveals her embrace of peptide therapy, detailing its benefits for energy and skin, and how it served as an alternative to GLP-1 medications like Ozempic. Explore the growing world of peptide treatments.
6 min read
Peptide Panic: Why 'Plateau Panic' Hits Hard When Suppliers Disappear
The abrupt closure of a major peptide supplier has sent shockwaves through the patient community, revealing the inherent risks of gray-market access and highlighting the critical need for regulated, physician-guided peptide therapy.
8 min read
GLP-1 Weight Loss: Why Consistency Matters for Ozempic & Wegovy
Recent preclinical research suggests that inconsistent use of GLP-1 medications like Ozempic and Wegovy may diminish their effectiveness over time. Discover the science behind adherence and how to optimize your therapy.
9 min read
Jeremy Renner's Recovery: Peptide Therapy, Hyperbaric Treatment & Health Tracking
Actor Jeremy Renner shares his intense recovery journey following a near-fatal accident, detailing the use of peptide therapy, hyperbaric treatments, and the importance of data tracking in modern wellness.
9 min read
Peptide Therapy & The Biohacking Boom: Navigating Unregulated Wellness
The world of biohacking is increasingly embracing peptides, but what's the reality behind the hype? This article delves into the science, the risks of unregulated substances, and the potential impact of regulatory changes on access to these compounds.
10 min read
Peptides for Athletes: Separating Hype from Scientific Reality
Athletes are increasingly curious about peptides for performance enhancement and recovery. This article delves into the scientific literature to separate the hype from the reality, examining the evidence for popular peptides and their potential risks.
8 min read
Severe Obesity and Heart Failure: New Insights into Cardiac Muscle Recovery
A groundbreaking Johns Hopkins study reveals that severe obesity causes intrinsic cardiac muscle weakness, but weight loss can trigger significant recovery.
3 min read
Rebel Wilson Weight Loss: The Truth About GLP-1s, Lifestyle, and Sustainable Health
Rebel Wilson's transformation is more than a celebrity headline; it's a masterclass in metabolic health. Discover the role of GLP-1s, the science of consistency, and why moderation beats intensity.
2 min read
FDA Considers Compounding Access for Unproven Peptides: What Patients Need to Know
The FDA is evaluating the regulation of specific peptides amid growing demand. We break down the science, the risks, and the clinical implications.
2 min read
Generic Ozempic Semaglutide Gets Tentative USFDA Approval; OneSource CDMO Par...
A generic version of Ozempic semaglutide has received tentative USFDA approval, marking a key step toward affordable GLP-1 therapy. Orbicular spearheaded product development, partnering with OneSource Specialty Pharma as the CDMO for reliable U.S. market manufacturing. This collaboration promises steady commercial supply from an FDA-approved site.
5 min read
Lost 9 Stone on Mounjaro: Loose Skin Sparks ElastiK Skin Business
Marc McKee dropped nine stone with Mounjaro, transforming his health but leaving him with loose skin that inspired a new business. ElastiK Skin targets GLP-1 weight loss side effects using peptides, hyaluronic acid, and LED therapy. Early users report better hydration and elasticity with consistent use.
5 min read
Kathryn Thomas: Daughter Ellie 'Getting Her Head Around' Famous Mum
Irish broadcaster Kathryn Thomas reveals her eldest daughter Ellie is starting to grasp that her mum is a public figure, amid chats about fame and family. In her new documentary Young Forever: The Death of Ageing?, she explores aesthetics, Botox normalization, peptides, and biohacking for longevity. As a 47-year-old mum, she emphasizes aging as a privilege while focusing on health for her kids' milestones.
6 min read
Castle Rock Hormone Health: Redefining Longevity for High Performers
Cold plunge therapies and peptide regimens have gone mainstream among elite athletes and executives, but Castle Rock Hormone Health is elevating the game with comprehensive hormone optimization. Co-founded by Dr. Lee Moorer, the clinic targets the root causes of low energy and declining performance through advanced testing and tailored therapies. High performers are reporting clearer thinking, better sleep, and enhanced endurance.
5 min read
Wegovy Pill Shows Greater Weight Loss Than Foundayo in Novo Study
Novo Nordisk's latest comparison study claims its Wegovy pill delivers superior weight loss compared to Eli Lilly's newly approved Foundayo tablet. The ORION analysis shows a 3.2 percentage point edge for oral semaglutide, plus lower discontinuation rates due to side effects. As oral GLP-1s compete, discover the key findings and implications for patients.
6 min read
Kailera Therapeutics Eyes IPO for Obesity Drug Pipeline
Boston-based Kailera Therapeutics is gearing up for an IPO to fuel its obesity drug pipeline, including Phase III GLP-1/GIP agonist ribupatide. Backed by $400M Series A and $600M Series B, the company eyes superior profiles versus blockbusters like Zepbound. Despite $368.7M deficits, topline data looms large.
5 min read
FDA Approves Triple Max Dose of Wegovy: 7.2mg Now Available
The FDA just greenlit a groundbreaking higher dose of Wegovy, tripling the previous maximum to 7.2 milligrams for enhanced weight management. Patients saw up to 21% body weight loss, with unique cardiovascular protections. Here's what this means for obesity treatment and access.
5 min read
What to Do When Tirzepatide Stops Working: Shift to Retatrutide
If Tirzepatide worked initially but now you've hit a plateau, it's not failure—it's metabolic adaptation signaling the next phase. California Trim Clinic is leading the shift to retatrutide, a triple-pathway therapy targeting energy expenditure for sustained results. Patients are moving beyond plateaus with physician-guided care.
4 min read
The Quest for Oral GLP-1s: History and Innovations
For decades, GLP-1 receptor agonists like Ozempic have transformed diabetes and obesity treatment via injections, but patients crave oral options. This guide traces the scientific quest for oral GLP-1s, from early discoveries and Gila monster breakthroughs to Rybelsus challenges and promising algae-based innovations. Understand the barriers and what's next for affordable, pill-based metabolic health.
5 min read
Eli Lilly Invests $3B in China for Next-Gen Oral GLP-1 Drug Production
Eli Lilly is set to invest a substantial $3 billion in China over the next decade to bolster the production of its groundbreaking oral GLP-1 receptor agonist, Orforglipron. This strategic move aims to enhance supply chain capacity for a drug poised to treat type 2 diabetes and obesity.
8 min read
Aspen Plans Mounjaro Rollout in Sub-Saharan Africa
South Africa's Aspen Pharmacare is accelerating Mounjaro's rollout across sub-Saharan Africa after its explosive success at home, where the GLP-1 market tripled to $133.6 million. With over half the market share and $78.97 million in projected sales, this expansion tests rapid access to advanced weight-loss therapies. Here's how Aspen's KwikPen approval paves the way.
4 min read
Aspen Pharmacare Targets Semaglutide Generic Approval in Canada by September
Aspen Pharmacare Holdings Ltd. is aiming for regulatory approval of its copycat semaglutide version in Canada by September, positioning itself as a first-mover. CEO Stephen Saad shared this timeline in a recent interview, highlighting Canada's role as a benchmark for other nations. This development could enhance affordability of GLP-1 therapies like Ozempic.
5 min read
Zydus' ZYOG1: Oral GLP-1 Ahead of Ozempic by 15 Years
Fifteen years before Ozempic sparked the GLP-1 revolution, Zydus Lifesciences in India developed ZYOG1, a promising oral GLP-1 agonist. Showing preclinical benefits for glucose control, weight loss, and a clean safety profile, it earned phase I trial approval in 2010—but was shelved amid high costs. This untold story highlights India's early edge in peptide therapy.
5 min read
American Girl Dolls Get 'Ozempic' Makeover for Modern Era, Public Unimpressed
American Girl Dolls have undergone a controversial 'Ozempic' makeover, with slimmer bodies aimed at the 'modern era'—but many parents and influencers are far from impressed. The redesign highlights the cultural impact of GLP-1 medications like Ozempic on body ideals. Explore the debate, drug mechanisms, and health considerations.
5 min read
Soha Ali Khan Praises Aishwarya Mohanraj's Mounjaro Use for Weight Loss Amid ...
In a refreshing moment of candor amid the Ozempic debate, Bollywood actress Soha Ali Khan has praised influencer Aishwarya Mohanraj for admitting her use of Mounjaro for weight loss. This celebrity endorsement underscores growing openness about GLP-1 medications in entertainment circles. Discover the science behind these drugs and their implications for metabolic health.
5 min read
GLP-1 Envy Was Just the Beginning: Hims & Hers Super Bowl Ad
A Hims & Hers Super Bowl ad provocatively claims 'Rich people live longer,' selling telehealth access to GLP-1s, peptides, and testosterone like the elite. But as compounded drugs face DOJ scrutiny, is this democratizing care or risking safety? Dive into the ad, cultural envy, and expert concerns.
5 min read
Ozempic Weight Loss: Celebrity Rumors vs. Real Science
When Bollywood star Tamanna Bhatia appeared slimmer, social media buzzed with Ozempic accusations, sparking debates on beauty standards and rapid weight loss. Beyond the rumors, Ozempic (semaglutide) is a powerful GLP-1 drug transforming weight management. This guide dives into the science, risks, and healthier paths forward.
5 min read
Ozempic Rebound: Weight Regain After Stopping GLP-1 Drugs
GLP-1 drugs like Ozempic promise dramatic weight loss, but what happens when you stop? Studies reveal rapid regain—often half or more of lost weight—due to rebound hunger and metabolic shifts. This guide breaks down the mechanisms, evidence, and sustainable strategies.
5 min read
Oral Wegovy Pill: Novo Nordisk's Game-Changer for Obesity
Novo Nordisk's launch of an oral Wegovy pill marks a pivotal shift in GLP-1 therapy, offering a convenient alternative to injections for obesity treatment. This guide explores its mechanism, efficacy, safety profile, and how it stacks up against rivals like Eli Lilly's orforglipron. Learn what this means for your weight loss journey.
4 min read
Mounjaro Weight Regain: Why It Happens Fast & How to Fight It
Many users like the author experience devastating weight regain shortly after stopping Mounjaro, mirroring real-world and trial data. This guide unpacks the physiology, backed by studies, and offers practical steps to sustain your progress. Don't let hard-won losses slip away—arm yourself with knowledge.
5 min read
Roche CT-388: 22.5% Weight Loss Tops Wegovy in Phase 2 Trial
Roche's experimental obesity drug CT-388 delivered impressive 22.5% average weight loss in a phase 2 trial, surpassing Novo Nordisk's Wegovy and rivaling Eli Lilly's Zepbound. Over half of participants resolved obesity by dropping below a BMI of 30. This positions Roche as a serious contender in the booming GLP-1 market.
4 min read
Ozempic Weight Loss: Amanda Bynes' 28lb Transformation Explained
Amanda Bynes recently shared her 28-pound weight loss journey on Ozempic, dropping from 180lbs to 152lbs and feeling inspired. This celebrity story highlights the growing popularity of GLP-1 medications for weight management. Learn the science, evidence, and practical advice behind these powerful tools.
4 min read
GLP-1 Market Boom to $299B by 2033: Drugs & Insights
The GLP-1 analogues market is surging from $62.81B in 2024 to $299.08B by 2033, driven by rising diabetes and obesity rates. Drugs like Ozempic, Wegovy, Mounjaro, and Zepbound lead with proven efficacy in glycemic control and weight loss. This guide breaks down the science, market trends, and what patients should know.
4 min read
Retatrutide Explained: Triple Agonist Weight Loss Drug
Retatrutide is exploding on TikTok among gym enthusiasts for its potent weight loss effects, but it's not FDA-approved yet. This guide breaks down its triple-hormone mechanism, compares it to semaglutide and tirzepatide, and warns of black market risks. Learn why experts urge caution.
4 min read
GLP-1s & Asthma: How Peptide Therapy Could Improve Metabolic Health & Breathing
New research shows that GLP-1 receptor agonists may significantly reduce asthma exacerbations and the need for steroids in obese patients with asthma. This opens up promising new avenues in metabolic health and asthma management.
3 min read
GLP-1s & Hollywood: Decoding Clooney's Weight Loss Transformation
George Clooney's recent appearance sparked concerns about his health, with many attributing his weight loss to GLP-1 drugs like Ozempic. This raises important questions about the use of these medications and their impact on overall wellness and longevity.
3 min read
Unlocking Metabolic Secrets: How Bariatric Surgery Impacts Glucose
Bariatric surgery significantly impacts glucose and insulin responses. This post explores the nuances of these changes, focusing on the impact of different surgical procedures, sex-based differences, and the implications for personalized treatment of metabolic conditions.
3 min read
GLP-1s & Weight Loss: Separating Fact from Fiction in Reality TV
The use of GLP-1 medications for weight loss is a hot topic, even among reality TV stars. We break down the debate, explore healthier alternatives, and discuss the importance of holistic health tracking.
3 min read
GLP-1 Injections: Unexpected Heart Health Benefits Unveiled
New research reveals that GLP-1 weight loss injections, such as semaglutide, may offer significant heart health benefits independent of weight loss. This could change how we view and use these medications for long-term health.
3 min read
Revolutionizing Drug Discovery: AI and Peptide Therapy for Longevity
Artificial intelligence is revolutionizing the field of peptide therapy, drastically accelerating drug discovery timelines. This is especially promising for tackling complex diseases like Alzheimer's and advancing the field of longevity research.
3 min read